Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) Consolidated Net Income (2019 - 2025)

Historic Consolidated Net Income for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to -$25.6 million.

  • Innate Pharma's Consolidated Net Income rose 193.0% to -$25.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$106.5 million, marking a year-over-year decrease of 23635.95%. This contributed to the annual value of -$133652.4 for FY2022, which is 9840.63% up from last year.
  • Latest data reveals that Innate Pharma reported Consolidated Net Income of -$25.6 million as of Q2 2025, which was up 193.0% from -$48.6 million recorded in Q4 2024.
  • Innate Pharma's Consolidated Net Income's 5-year high stood at $7.5 million during Q2 2021, with a 5-year trough of -$48.6 million in Q4 2024.
  • For the 5-year period, Innate Pharma's Consolidated Net Income averaged around -$11.9 million, with its median value being -$6.2 million (2023).
  • Data for Innate Pharma's Consolidated Net Income shows a peak YoY increase of 89402.78% (in 2023) and a maximum YoY decrease of 461673871.47% (in 2023) over the last 5 years.
  • Innate Pharma's Consolidated Net Income (Quarter) stood at -$8.4 million in 2021, then soared by 100.0% to -$133.65 in 2022, then tumbled by 4616738.71% to -$6.2 million in 2023, then tumbled by 687.89% to -$48.6 million in 2024, then soared by 47.32% to -$25.6 million in 2025.
  • Its last three reported values are -$25.6 million in Q2 2025, -$48.6 million for Q4 2024, and -$26.1 million during Q2 2024.